Seeking Alpha


Send Message
View as an RSS Feed
Latest  |  Highest rated
  • Merck (MRK) and Pfizer (PFE) enter into a 60/40 worldwide agreement to jointly develop and commercialize PFE's type 2 diabetes treatment ertugliflozin which should enter Phase III trials later this year. As part of the deal, PFE received $60M upfront and may receive additional payments in the future. (PR[View news story]
    One has to wonder why PFE is doing a joint venture with MCK when it certainly can afford to do it solo.
    Apr 29, 2013. 10:02 AM | Likes Like |Link to Comment
  • Pfizer's (PFE) anti-smoking drug Chantix produced a higher rate of heart attacks or strokes in patients using the treatment than those who didn’t, the FDA said today in a safety notice on its website. According to an analysis of clinical trials, the number of cardiovascular issues in patients on Chantix and those who took a placebo was uncommon. While the increased risk wasn’t statistically significant for those on Chantix, the FDA thinks it's “more likely that it is related to the drug and not purely a chance finding.” [View news story]
    The "summary" also indicates that, while the CV mortality was higher in the Chantix group (not statistically significant), the all-cause mortality was lower in the Chantix group (also not statistically significant). Clinical significance was not addressed. Meta analysis,while of some value, often compares studies that are not truly comparable. I suspect that this information will influence many smokers to stop (or never start) using Chantix. I doubt that this is a good outcome.
    Dec 13, 2012. 02:31 AM | 1 Like Like |Link to Comment
1 Like